1P-LSD

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
1P-LSD
1P-LSD Structural Formulae V.1.svg
Legal status
Legal status
  • DE: NpSG (Industrial and scientific use only)
  • UK: Under Psychoactive Substances Act
  • Illegal in Czech Republic, Denmark, Estonia, Japan, Latvia, Norway, Romania, Singapore, Sweden, Switzerland
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC23H29N3O2
Molar mass379.504 g·mol−1
3D model (JSmol)

1P-LSD or 1-propionyl-lysergic acid diethylamide is a psychedelic drug of the lysergamide class that is a derivative and functional analogue of LSD and a homologue of ALD-52. It has been sold online as a designer drug since 2015.[1][2][3][4][5][6] It modifies the LSD molecule by adding a propionyl group to the nitrogen molecule of LSD's indole.

Pharmacology[edit]

In mice, 1P-LSD produces LSD-like effects with 38% the potency of LSD and it is therefore classed as a serotonergic hallucinogen.[7] However, 1P-LSD itself is unable to bind to the serotenergic 5-HT2A receptors.[8][9] But since LSD is detected when 1P-LSD is incubated in human serum,[7] 1P-LSD acts, at least in part, as a prodrug for LSD.[10]

Effects[edit]

1P-LSD on blotter paper

The effects profile of 1P-LSD is not well defined in the scientific literature. It is generally thought to be comparable to that of LSD.[11] Many anecdotal reports indicate that 1P-LSD has a slightly shorter duration than LSD in humans, with the majority of users stating that they cannot distinguish the qualitative effects of 1P-LSD from LSD.[citation needed]

Legal status[edit]

1P-LSD is a controlled substance in Finland,[12] Denmark,[13] Germany,[14] Estonia,[15] Japan,[16] Latvia,[17] Norway,[18] Romania,[19] Sweden,[20] Switzerland,[21] United Kingdom, Singapore[22] and the Czech Republic.[23]

See also[edit]

References[edit]

  1. ^ "Philtre Bulletin Issue 5" (PDF). WEDINOS. March 2015. Retrieved 28 July 2015.
  2. ^ Max Daly (27 July 2015). "Why Young Brits Are Taking So Much LSD and Ecstasy". Vice. Retrieved 11 August 2015.
  3. ^ "Newer Unregulated Drugs" (PDF). KFx. April 2015. Retrieved 13 August 2015.
  4. ^ Speiser M (11 August 2015). "A handful of dangerous new legal drugs has public health experts worried". Business Insider UK. Retrieved 13 August 2015.
  5. ^ "1P-LSD". New Synthetic Drugs Database. Archived from the original on 2016-07-03. Retrieved 2016-01-29.
  6. ^ Palamar JJ, Acosta P, Sherman S, Ompad DC, Cleland CM (November 2016). "Self-reported use of novel psychoactive substances among attendees of electronic dance music venues". The American Journal of Drug and Alcohol Abuse. 42 (6): 624–632. doi:10.1080/00952990.2016.1181179. PMC 5093056. PMID 27315522.
  7. ^ a b Brandt SD, Kavanagh PV, Westphal F, Stratford A, Elliott SP, Hoang K, et al. (September 2016). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)". Drug Testing and Analysis. 8 (9): 891–902. doi:10.1002/dta.1884. PMC 4829483. PMID 26456305.
  8. ^ Jose (15 October 2015). "Is 1P-LSD A Prodrug To LSD?". Detect-Kit. Archived from the original on 2015-10-15. Retrieved 15 October 2015.
  9. ^ Linda P, Stener A, Cipiciani A, Savelli G (January–February 1983). "Hydrolysis of amides. Kinetics and mechanism of the basic hydrolysis of N-acylpyrroles, N-acylindoles and N-acylcarbazoles". Journal of Heterocyclic Chemistry. 20 (1): 247–248. doi:10.1002/jhet.5570200154.
  10. ^ Grumann, Christina; Henkel, Kerstin; Brandt, Simon D.; Stratford, Alexander; Passie, Torsten; Auwärter, Volker (May 2020). "Pharmacokinetics and subjective effects of 1P-LSD in humans after oral and intravenous administration". Drug Testing and Analysis. 12 (8): 1144–1153. doi:10.1002/dta.2821. ISSN 1942-7611. PMID 32415750.
  11. ^ Schifano F, Orsolini L, Papanti D, Corkery J (June 2016). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. 32: 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. OCLC 643052237. PMID 27272067.
  12. ^ "Valtioneuvoston asetus kuluttajamarkkinoilta kielletyistä psykoaktiivisista aineista annetun valtioneuvoston asetuksen liitteen muuttamisesta" [Government decree amending the annex to the government decree on psychoactive substances prohibited on the consumer market] (in Finnish).
  13. ^ "Lists of euphoriant substances". The Danish Medicines Agency. September 2015.
  14. ^ "Verordnung zur Änderung der Anlage des Neue-psychoaktive-. Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes" [Regulation amending the Annex to the New Psychoactive Substances Act and Appendices to the Narcotics Act] (in German).
  15. ^ "Muudatus narkootiliste ja psühhotroopsete ainete I nimekirjas" (in Estonian). Republic of Estonia Agency of Medicines.
  16. ^ "指定薬物一覧" (PDF) (in Japanese). Ministry of Health, Labour and Welfare.
  17. ^ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). Latvijas Republikas tiesību akti.
  18. ^ "31 Forskrift om narkotika (narkotikaforskriften)" (in Norwegian). Helse- og omsorgsdepartementet. 14 February 2013.
  19. ^ "Legea 194/2011 privind combaterea operatiunilor cu produse susceptibile de a avea efecte psihoactive, altele decat cele prevazute de acte normative in vigoare, republicata 2014". www.dreptonline.ro. Retrieved 2020-07-24.
  20. ^ "Förordning om ändring i förordningen (1999:58) om förbud mot vissa hälsofarliga varor" [Ordinance (1999: 58) on the prohibition of certain dangerous goods] (PDF) (in Swedish).
  21. ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat.
  22. ^ "Misuse of Drugs Act - Singapore Statutes Online". sso.agc.gov.sg.
  23. ^ "Nařízení vlády č. 463/2013 Sb. Nařízení vlády o seznamech návykových látek" (in Czech). Zákony pro lidi.